ATE516801T1 - Kristalline form eines gamma-aminobuttersäure- analogons - Google Patents

Kristalline form eines gamma-aminobuttersäure- analogons

Info

Publication number
ATE516801T1
ATE516801T1 AT04795177T AT04795177T ATE516801T1 AT E516801 T1 ATE516801 T1 AT E516801T1 AT 04795177 T AT04795177 T AT 04795177T AT 04795177 T AT04795177 T AT 04795177T AT E516801 T1 ATE516801 T1 AT E516801T1
Authority
AT
Austria
Prior art keywords
crystalline form
aminobutyric acid
analogon
gamma
methods
Prior art date
Application number
AT04795177T
Other languages
English (en)
Inventor
Tono Estrada
Stephen P Raillard
Christine Frauenfelder
Uwe Zacher
Original Assignee
Xenoport Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenoport Inc filed Critical Xenoport Inc
Application granted granted Critical
Publication of ATE516801T1 publication Critical patent/ATE516801T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04795177T 2003-10-14 2004-10-14 Kristalline form eines gamma-aminobuttersäure- analogons ATE516801T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51128703P 2003-10-14 2003-10-14
PCT/US2004/033979 WO2005037784A2 (en) 2003-10-14 2004-10-14 Crystalline form of gamma-aminobutyric acid analog

Publications (1)

Publication Number Publication Date
ATE516801T1 true ATE516801T1 (de) 2011-08-15

Family

ID=34465215

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04795177T ATE516801T1 (de) 2003-10-14 2004-10-14 Kristalline form eines gamma-aminobuttersäure- analogons

Country Status (22)

Country Link
US (10) US8026279B2 (de)
EP (1) EP1677767B1 (de)
JP (2) JP4308263B2 (de)
KR (1) KR101096480B1 (de)
CN (1) CN1867322B (de)
AT (1) ATE516801T1 (de)
AU (1) AU2004282192B2 (de)
BR (1) BRPI0415288B8 (de)
CA (1) CA2541752C (de)
DK (1) DK1677767T3 (de)
ES (1) ES2368916T3 (de)
IL (2) IL174600A (de)
MX (1) MXPA06004088A (de)
NO (1) NO338275B1 (de)
NZ (1) NZ546381A (de)
PL (1) PL1677767T3 (de)
PT (1) PT1677767E (de)
RU (1) RU2412162C2 (de)
SG (1) SG147437A1 (de)
SI (1) SI1677767T1 (de)
WO (1) WO2005037784A2 (de)
ZA (1) ZA200602722B (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) * 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7025745B2 (en) * 2002-10-07 2006-04-11 Advanced Cardiovascular Systems, Inc. Method of making a catheter balloon using a tapered mandrel
JP2007505149A (ja) * 2003-09-11 2007-03-08 ゼノポート，インコーポレイティド ギャバ類似体のプロドラッグを用いる尿失禁の治療および／あるいは予防
SG146643A1 (en) * 2003-09-17 2008-10-30 Xenoport Inc Treating or preventing restless legs syndrome using prodrugs of gaba analogs
KR101096480B1 (ko) 2003-10-14 2011-12-20 제노포트 인코포레이티드 감마-아미노부티르산 유사체의 결정질 형태
US20050209319A1 (en) * 2004-03-18 2005-09-22 Xenoport, Inc. Treatment of local pain
WO2006050514A1 (en) 2004-11-04 2006-05-11 Xenoport, Inc. Gabapentin prodrug sustained release oral dosage forms
JP4938771B2 (ja) * 2005-06-20 2012-05-23 ゼノポート，インコーポレーテッド トラネキサム酸のカルバミン酸アシルオキシアルキルプロドラッグ、合成法、および使用
MX2009006080A (es) * 2006-12-08 2009-07-14 Xenoport Inc Uso de profarmacos de analogos de gaba para el tratamiento de enfermedades.
WO2008086492A1 (en) * 2007-01-11 2008-07-17 Xenoport, Inc. Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
US20090118365A1 (en) * 2007-11-06 2009-05-07 Xenoport, Inc Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain
US20090318728A1 (en) * 2008-06-24 2009-12-24 Teva Pharmaceutical Industries Ltd. Processes for preparing prodrugs of gabapentin and intermediates thereof
TW201006789A (en) * 2008-07-02 2010-02-16 Teva Pharma Gabapentin enacarbil salts and processes for their preparation
US8299291B2 (en) * 2008-08-07 2012-10-30 Xenoport, Inc. Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
WO2010017498A1 (en) 2008-08-07 2010-02-11 Xenoport, Inc. Methods of synthesizing n-hydroxysuccinimidyl carbonates
US8283487B2 (en) 2008-11-26 2012-10-09 Teva Pharmaceutical Industries Ltd. Processes for the preparation and purification of gabapentin enacarbil
US20100160666A1 (en) * 2008-12-23 2010-06-24 Teva Pharmaceutical Industries Ltd. Preparation of gabapentin enacarbil intermediate
TW201032792A (en) * 2009-03-02 2010-09-16 Astellas Pharma Inc Package of solid pharmaceutical preparation
AU2010221270B2 (en) * 2009-03-03 2014-02-27 Xenoport, Inc. Sustained release oral dosage forms of an R-baclofen prodrug
KR20110126747A (ko) * 2009-03-06 2011-11-23 제노포트 인코포레이티드 고용량의 가바펜틴 프로드러그를 갖는 경구 투여 제형
WO2011028234A1 (en) * 2009-09-04 2011-03-10 Xenoport, Inc. Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid
US20110184060A1 (en) 2010-01-22 2011-07-28 Xenoport, Inc. Oral dosage forms having a high loading of a tranexamic acid prodrug
WO2011133675A1 (en) * 2010-04-21 2011-10-27 Teva Pharmaceutical Industries Ltd. Gabapentin enacarbil compositions
WO2013008182A1 (en) * 2011-07-10 2013-01-17 Mahesh Kandula Prodrugs of gaba analogs
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
WO2013168019A1 (en) * 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neuropathic pain
CN104603096A (zh) 2012-05-07 2015-05-06 塞利克斯比奥私人有限公司 用于治疗神经肌肉障碍和神经退行性疾病的组合物和方法
WO2013167985A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013175377A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of mucositis
CA2873098A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
EP2852570B1 (de) 2012-05-23 2020-04-22 Cellixbio Private Limited Zusammensetzung zur behandlung von entzündlicher darmerkrankung
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
CN104364231A (zh) 2012-09-08 2015-02-18 塞利克斯比奥私人有限公司 用于治疗炎症和脂质异常的组合物和方法
HK1219268A1 (zh) 2013-02-26 2017-03-31 Xenoport, Inc. 1-(酰氧基)-烷基氨基甲酸酯化合物的制造方法
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
CA2914461A1 (en) 2013-06-04 2014-12-11 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
NZ736131A (en) 2014-09-26 2019-04-26 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
JP6698643B2 (ja) 2014-09-29 2020-05-27 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 多発性硬化症の治療のための組成物及び方法
SG11201703369WA (en) 2014-10-27 2017-05-30 Cellix Bio Private Ltd Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
DK3242869T3 (da) 2015-01-06 2022-01-31 Cellix Bio Private Ltd Sammensætninger og fremgangsmåder til behanding af inflammation og smerte
RU2739192C1 (ru) * 2020-06-18 2020-12-21 федеральное государственное бюджетное образовательное учреждение высшего образования «Омский государственный медицинский университет» Министерства здравоохранения Российской Федерации (ФГБОУ ВО ОмГМУ Минздрава России) Способ лечения абстинентного синдрома, с целью превенции развития психоза, у лиц с зависимостью от синтетических агонистов рецепторов гамма-аминомасляной кислоты: бутиролактона, 1,4-бутандиола

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
JPS62258337A (ja) 1986-04-30 1987-11-10 Kuraray Co Ltd ４−ヒドロキシ−２，４，６−トリメチル−２，５−シクロヘキサジエン−１−オンの精製法
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
DE3928183A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US5084169A (en) 1989-09-19 1992-01-28 The University Of Colorado Foundation, Inc. Stationary magnetically stabilized fluidized bed for protein separation and purification
US5084479A (en) 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
AU9137091A (en) 1990-11-27 1992-06-25 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
FI945426A0 (fi) 1992-05-20 1994-11-18 Univ Northwestern GABA- ja L-glutamiinihappoanalogit kohtauksenvastaiseen käsittelyyn
DE69712877T2 (de) 1996-02-07 2002-11-14 Warner-Lambert Co., Morris Plains Zyklischaminosäure als pharmazeutische mittel
JP2000506862A (ja) 1996-03-14 2000-06-06 ワーナー―ランバート・コンパニー 医薬としての新規な架橋環状アミノ酸
SK283295B6 (sk) 1996-03-14 2003-05-02 Warner-Lambert Company Substituovaná cyklická aminokyselina, jej použitie a farmaceutický prostriedok na jej báze
NZ332762A (en) 1996-07-24 2000-09-29 Warner Lambert Co Isobutylgaba and its derivatives for the treatment of pain
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
JP2002514187A (ja) 1996-10-23 2002-05-14 ワーナー―ランバート・コンパニー 薬剤としての置換γ―アミノ酪酸
AU8668598A (en) 1997-08-20 1999-03-08 University Of Oklahoma, The Gaba analogs to prevent and treat gastrointestinal damage
CA2303244C (en) 1997-10-27 2005-12-06 Warner-Lambert Company Cyclic amino acids and derivatives thereof useful as pharmaceutical agents
KR20010033153A (ko) 1997-12-16 2001-04-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 4(3)-치환-4(3)-아미노메틸-(티오)피란 또는 -피페리딘유도체(=가바펜틴 동족체), 그의 제법 및 신경 질환 치료용도
JP2002508362A (ja) 1997-12-16 2002-03-19 ワーナー−ランバート・カンパニー １−置換−１−アミノメチル−シクロアルカン誘導体（＝ガバペンチン類縁体）、その製造および神経学的疾患の治療におけるその使用
TR200001794T2 (tr) 1997-12-16 2000-10-23 Warner-Lambert Company Farmasötik maddeler olarak yeni aminler
US6605610B1 (en) 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
CA2309354A1 (en) 1998-01-23 1999-07-29 Leslie Magnus-Miller Gabapentin and its derivatives for the treatment of muscular and skeletal pain
WO1999061424A1 (en) 1998-05-26 1999-12-02 Warner-Lambert Company Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
AUPP396998A0 (en) 1998-06-09 1998-07-02 University Of Melbourne, The A method for increasing the permeability of wood
ES2279631T3 (es) 1998-10-16 2007-08-16 Warner-Lambert Company Llc Uso de analogos de gaba para la fabricaion de un medicamento para el tratamiento de mania y trastornos bipolares.
AU1602100A (en) 1998-11-25 2000-06-13 Warner-Lambert Company Improved gamma amino butyric acid analogs
EP1031350A1 (de) 1999-02-23 2000-08-30 Warner-Lambert Company Verwendung eines Gabapentin-Analogen zur Herstellung eines Arzneimittels zur Prophylaxe und Behandlung von Eingeweideschmerzen
ATE463242T1 (de) 1999-04-08 2010-04-15 Warner Lambert Co Behandlung von inkontinenz
US6992109B1 (en) 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
US6310098B1 (en) 1999-07-22 2001-10-30 University Of Rochester Method of treating symptoms of hormonal variation, including hot flashes
GB2362646A (en) 2000-05-26 2001-11-28 Warner Lambert Co Cyclic amino acid derivatives useful as pharmaceutical agents
KR100785182B1 (ko) 2000-06-26 2007-12-11 워너-램버트 캄파니 엘엘씨 수면 장애를 위한 가바펜틴 유사체
GB2365425A (en) 2000-08-01 2002-02-20 Parke Davis & Co Ltd Alkyl amino acid derivatives useful as pharmaceutical agents
US6992076B2 (en) 2000-10-06 2006-01-31 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
US6900192B2 (en) 2000-10-06 2005-05-31 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
EP1358200A4 (de) 2000-10-06 2005-07-20 Xenoport Inc Von gallensäure abgeleitete verbindungen zur verbesserung der oralen absorption und systemischen bioverfügbarkeit von arzneistoffen
GB2368579A (en) 2000-10-31 2002-05-08 Parke Davis & Co Ltd Azole pharmaceutical agents
AU2002239257A1 (en) 2000-11-17 2002-06-03 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
JP2002346303A (ja) 2001-05-28 2002-12-03 Mitsubishi Chemicals Corp 晶析方法
JP2002355501A (ja) 2001-05-30 2002-12-10 Sumitomo Chem Co Ltd 滴下晶析方法
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
CA2449729C (en) 2001-06-11 2009-11-03 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
WO2003077902A1 (en) 2002-02-19 2003-09-25 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
EP1608357A4 (de) 2003-03-31 2008-03-26 Xenoport Inc Behandlung oder prävention von hitzewallungen unter verwendung von prodrugs von gaba-analoga
US6816787B2 (en) 2003-03-31 2004-11-09 Schlumberger Technology Corporation Generating and displaying a virtual core and a virtual plug associated with a selected piece of the virtual core
US7662987B2 (en) 2003-07-15 2010-02-16 Xenoport, Inc. Methods for synthesis of acyloxyalkyl compounds
JP2007505149A (ja) 2003-09-11 2007-03-08 ゼノポート，インコーポレイティド ギャバ類似体のプロドラッグを用いる尿失禁の治療および／あるいは予防
SG146643A1 (en) 2003-09-17 2008-10-30 Xenoport Inc Treating or preventing restless legs syndrome using prodrugs of gaba analogs
KR101096480B1 (ko) 2003-10-14 2011-12-20 제노포트 인코포레이티드 감마-아미노부티르산 유사체의 결정질 형태
CA2551859C (en) 2003-12-30 2011-10-04 Xenoport, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
US20050209319A1 (en) 2004-03-18 2005-09-22 Xenoport, Inc. Treatment of local pain
WO2006050514A1 (en) * 2004-11-04 2006-05-11 Xenoport, Inc. Gabapentin prodrug sustained release oral dosage forms
MX2009005114A (es) 2006-11-14 2009-07-16 Xenoport Inc Uso de los profarmacos gabapentina y pregabalina para tratar el tinnitus.
MX2009006080A (es) 2006-12-08 2009-07-14 Xenoport Inc Uso de profarmacos de analogos de gaba para el tratamiento de enfermedades.

Also Published As

Publication number Publication date
US20200283376A1 (en) 2020-09-10
US8686034B2 (en) 2014-04-01
KR20070017977A (ko) 2007-02-13
DK1677767T3 (da) 2011-10-24
NO20062112L (no) 2006-07-12
US20100056632A1 (en) 2010-03-04
NO338275B1 (no) 2016-08-08
EP1677767A4 (de) 2008-03-05
US20190152900A1 (en) 2019-05-23
US20220251031A1 (en) 2022-08-11
IL174600A0 (en) 2006-08-20
BRPI0415288B1 (pt) 2019-05-14
WO2005037784A2 (en) 2005-04-28
EP1677767B1 (de) 2011-07-20
BRPI0415288A (pt) 2006-12-19
JP2007508396A (ja) 2007-04-05
PT1677767E (pt) 2011-10-13
US9150503B2 (en) 2015-10-06
EP1677767A2 (de) 2006-07-12
HK1090850A1 (en) 2007-01-05
US8026279B2 (en) 2011-09-27
US20050154057A1 (en) 2005-07-14
BRPI0415288B8 (pt) 2021-05-25
CN1867322B (zh) 2014-06-25
CA2541752C (en) 2012-01-03
JP4308263B2 (ja) 2009-08-05
US20140235710A1 (en) 2014-08-21
US20150353483A1 (en) 2015-12-10
AU2004282192A1 (en) 2005-04-28
CN1867322A (zh) 2006-11-22
ES2368916T3 (es) 2011-11-23
SI1677767T1 (sl) 2011-11-30
IL174600A (en) 2014-05-28
MXPA06004088A (es) 2006-06-27
AU2004282192B2 (en) 2011-01-20
KR101096480B1 (ko) 2011-12-20
US20110313036A1 (en) 2011-12-22
ZA200602722B (en) 2008-04-30
WO2005037784A3 (en) 2005-06-23
JP4913796B2 (ja) 2012-04-11
US20110021628A1 (en) 2011-01-27
NZ546381A (en) 2010-01-29
CA2541752A1 (en) 2005-04-28
RU2006116470A (ru) 2007-11-20
IL202603A (en) 2014-11-30
SG147437A1 (en) 2008-11-28
JP2009149648A (ja) 2009-07-09
PL1677767T3 (pl) 2011-12-30
RU2412162C2 (ru) 2011-02-20
US20170183296A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
ATE516801T1 (de) Kristalline form eines gamma-aminobuttersäure- analogons
NO20065329L (no) Fremstilling av pregabalin og beslektede forbindelser.
IL183237A0 (en) Polymorphs of memantine hydrochloride
DK2023918T3 (da) Cyclosporiner til behandlingen og forebyggelse af okulære lidelser
ATE499109T1 (de) Zusammensetzung zur proteasomhemmung
WO2004108894A3 (en) Methods and compositions for amino acid production
NO20080580L (no) Serumfritt kulturmedium for produksjon av redkombinante gonadotropiner
EA200401515A1 (ru) Новые фармацевтические композиции, содержащие флибансерин в полиморфной модификации а
DE112006002769A5 (de) Bodenverbesserungsmittel und Verfahren zu dessen Herstellung
UY27618A1 (es) Ésteres hidroxamato de ácido n-(4-fenil-sustituido)-antranílico
IN2012DN02609A (de)
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof
WO2010119266A3 (en) Periodontal training
DE50214512D1 (de) Verfahren zur fruchtausdünnung
AU2003257583A1 (en) Tooth model for dentistry practical training
WO2007027477A3 (en) Treating vulvodynia using prodrugs of gaba analogs
EA200300272A1 (ru) Новые производные хиназолина, способ их получения и фармацевтические композиции, содержащие их
WO2005037219A3 (en) Disinfecting teat care compositions
AU2003293579A1 (en) Cyclohexane derivatives and methods for their preparation
WO2006012351A3 (en) Markers for brain damage
MX2007002917A (es) Todo-trans-retinol: todo-trans-13, 14-dihidrorretinol saturasa y metodos de uso de la misma.
DE602005016282D1 (de) Verfahren zur herstellung von camptothecin-derivaten
SG145759A1 (en) Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
CY1113583T1 (el) Κρυσταλλικη μορφη αναλογου του γαμμα-αμινοβουτυρικου οξεος
DE602005026035D1 (en) Festphasenpeptidsynthese

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1677767

Country of ref document: EP